Celltrion Sets Sights on 2030 With Expanded Biosimilar Portfolio, Market Reach

Making the Cost of IBD Care Sustainable

November 2nd 2024

By Deana Ferreri, PhD

Panelists Stress Stakeholder Education to Build Confidence in Biosimilars

October 31st 2024

By Skylar Jeremias

By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.

Biosimilars Development Roundup: October 2024

October 31st 2024

By Skylar Jeremias

In October, the GRx+Biosims conference included discussions on data transparency, artificial intelligence, and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.

Enhancing Adoption of Infused Biosimilars for a Sustainable Future

October 30th 2024

By Skylar Jeremias

An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.

Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry

October 29th 2024

By Skylar Jeremias

Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.

How Policy Reforms in PBM Systems Could Change the Adalimumab Market

October 28th 2024

By Skylar Jeremias

Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve accessibility, affordability, and fair competition for adalimumab biosimilars.

Veterans’ Experience With Infliximab Biosimilars for IBD Treatment

October 26th 2024

By Deana Ferreri, PhD

A study of the Veterans Health Administration detailed their experience with infliximab biosimilars in a population of patients with inflammatory bowel disease (IBD) who were naive to infliximab.

Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf

October 25th 2024

By Skylar Jeremias

At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.

The Top 5 Biosimilar Articles for the Week of October 21

October 25th 2024

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of October 21, 2024.

FDA and Industry Experts Unpack Biosimilar Device Requirements

October 23rd 2024

By Skylar Jeremias

At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.